Atrial Fibrillation Market

DelveInsight's "Atrial Fibrillation Market Insights, Epidemiology, and Market Forecast — 2032" report delivers an in-depth understanding of the Atrial Fibrillation, historical and forecasted epidemiology as well as the Atrial Fibrillation market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

The Atrial Fibrillation market report provides current treatment practices, emerging drugs, Atrial Fibrillation market share of the individual therapies, current and forecasted Atrial Fibrillation market size from 2019 to 2032 segmented by seven major markets. The report also covers current Atrial Fibrillation treatment practice/algorithm, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, Spain) and the United Kingdom
• Japan

Study Period: 2019–2032

Atrial Fibrillation Treatment Algorithm and Disease Understanding

The DelveInsight’s Atrial Fibrillation market report gives a thorough understanding of Atrial Fibrillation by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. Atrial Fibrillation is an abnormal heart rhythm (arrhythmia) characterized by the rapid and irregular beating of the atrial chambers of the heart. It often begins as short periods of abnormal beating which become longer or continuous over time. It may also start as other forms of arrhythmia such as atrial flutter that then transform into AF. Often episodes have no symptoms. Occasionally there may be heart palpitations, fainting, lightheadedness, shortness of breath, or chest pain. The three following primary forms of Atrial Fibrillation have been categorized with regards to the duration of the episode:

The first type is Intermittent or paroxysmal Atrial Fibrillation, which occurs spontaneously and generally resolves by itself or with treatment within 7 days. It is characterized by episodes of irregular heart rhythm, which can occur with varying frequencies and periods before stopping. The second type is persistent Atrial Fibrillation in which sustained abnormal heart rhythm for more than 7 days even with treatment or direct current cardioversion. Despite this, persistent Atrial Fibrillation may eventually cease on its own or via treatment. The third type is long standing persistent Atrial Fibrillation, it is defined as lasting longer than 12 months, with the term permanent Atrial Fibrillation used when all means of treatment to restore normal heart rhythm have failed.

Atrial Fibrillation is linked to several forms of cardiovascular disease but may occur in otherwise normal hearts. Cardiovascular factors known to be associated with the development of Atrial Fibrillation include high blood pressure, coronary artery disease, mitral valve stenosis, mitral regurgitation, left atrial enlargement, hypertrophic cardiomyopathy (HCM), pericarditis, congenital heart disease, and previous heart surgery.

Atrial Fibrillation is a significant risk factor for stroke; stroke risk is higher in people with Atrial Fibrillation than in those without it. It can often go undetected, as it can be asymptomatic.

Atrial Fibrillation Diagnosis

The history and physical examination are focused on identifying risk factors, comorbidities, and physical findings of atrial fibrillation. The physical examination involves the assessment of blood pressure, heart rate, presence of cardiac murmurs (such as aortic or mitral stenosis), and evidence of heart failure (pulmonary rales, S3 gallop, peripheral pulses, and jugular venous distention). Additionally, initial blood tests that include a complete blood count, an electrolyte panel, thyroid-stimulating hormone, and liver and kidney function tests is done and imaging helps to evaluate cardiac structure and function, and chest radiography to assess for pulmonary disease.

Atrial Fibrillation Treatment

The cornerstones of Atrial Fibrillation management are rate control, anticoagulation and rhythm control for those symptomatically limited by Atrial Fibrillation. The clinical decision to use a rhythm-control or rate-control strategy requires an integrated consideration of several factors, including degree of symptoms, likelihood of successful cardioversion, presence of comorbidities, and candidacy for AF ablation. Warfarin represents the cornerstone of anticoagulant therapy for patients at moderate to high risk of thromboembolic events. Some patients may not be able to take anticoagulants because of contraindications or comorbidities. The goal of antiarrhythmic drug therapy is to reduce the duration and frequency of atrial fibrillation episodes, thus improving patient quality of life and symptoms. If successful, rhythm control can eliminate or delay the need for long-term anticoagulation with warfarin in some patients. Several antiarrhythmic drugs are commonly used to prevent atrial fibrillation recurrence, such as quinidine, flecainide, propafenone, sotalol, and dofetilide. Other antiarrhythmic agents, such as amiodarone, are used in an off-label fashion with great clinical efficacy.

Atrial Fibrillation Epidemiology

The Atrial Fibrillation epidemiology section provides insights about historical and current Atrial Fibrillation patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

• According to the study conducted by Rosenthal et al. (2016), Atrial Fibrillation is the most frequently encountered cardiac arrhythmia. It affects more than 2.7 to 6.1 million persons in the United States. AF is strongly age-dependent, affecting 4% of individuals older than 60 years and 8% of persons older than 80 years. Approximately 25% of individuals aged 40 years and older will develop AF during their lifetime.
• According to a study by Chung et al. (2021), in the UK, there are an estimated 1.5 million individuals living with AF, similar to the number of people with MI and exceeding those of cerebrovascular diseases and heart failure in 2020. Additionally, the prevalence of Atrial Fibrillation varies with age and sex. It is present in 0.12%–0.16% of those younger than 49 years, in 3.7%–4.2% of those aged 60–70 years, and in 10%–17% of those aged 80 years or older. In addition, it occurs more frequently in males, with a male to female ratio of 1.2:1. The incidence of AF ranges between 0.21 and 0.41 per 1,000 person/years (Berisso et al., 2014).
• The disease epidemiology covered in the report provides historical as well as forecasted Atrial Fibrillation epidemiology [segmented as Total Prevalent Cases of Atrial Fibrillation, Diagnosed and Treatable cases of Atrial Fibrillation, Gender-specific Prevalent cases of Atrial Fibrillation, Age-specific Prevalent cases of Atrial Fibrillation, and Type-specific cases of Atrial Fibrillation in the 7MM covering the United States, EU4 (Germany, France, Italy Spain) and the United Kingdom, and Japan from 2019 to 2032.

Country Wise-Atrial Fibrillation Epidemiology

This section provides glimpse of the Atrial Fibrillation epidemiology in the United States, EU4 (Germany, France, Italy Spain) and the United Kingdom, and Japan.

Atrial Fibrillation Recent Developments

• On November 25, 2024, Ohio-based S4 Medical Corp received FDA 510(k) approval for its redesigned eSolution® esophageal deviation device, making it the first FDA-approved device to prevent esophageal injury across all atrial fibrillation ablation modalities.
• On November 13, 2024, Fourth Frontier announced that its Frontier X Plus ECG monitor received FDA 510(k) clearance. The wearable device wirelessly transmits real-time ECG data and uses advanced algorithms to classify cardiac rhythms, including Bradycardia, Tachycardia, and Atrial Fibrillation. It demonstrated excellent signal quality during exercise and showed equivalence to a 12-lead ECG in clinical trials conducted in the U.S. and India.
• On November 8, 2024, Johnson & Johnson MedTech announced FDA approval of the Varipulse pulsed field ablation (PFA) platform for treating drug-refractory paroxysmal atrial fibrillation (AF).
• On October 16, 2024, XYRA LLC, a private biopharmaceutical company focused on cardiac rhythm disorders, highlighted the impact of FDA-approved wearable Atrial Fibrillation (AF) monitoring devices. These devices have enabled the identification of patients with long episodes of AF (LEAF), who are at high risk for complications such as stroke, heart failure, and progression to permanent AF. The use of such wearable technology allows for earlier detection and intervention, potentially improving outcomes for those with AF.
• On October 10, 2024, Abbott revealed that it has reached significant new milestones to enhance its growing range of pulsed-field ablation (PFA) solutions in electrophysiology. These milestones include the early completion of participant enrollment in the VOLT-AF IDE Study, which is associated with the Volt™ PFA System, and the initiation of the FOCALFLEX trial, designed to evaluate the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ (SE), for treating patients with paroxysmal atrial fibrillation.

Atrial Fibrillation Drug Chapters

The drug chapter segment of the Atrial Fibrillation report encloses the detailed analysis of Atrial Fibrillation marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Atrial Fibrillation clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Atrial Fibrillation Emerging Drugs

Limited late-stage pipeline activities has been observed in Atrial Fibrillation, as per ClinicalTrials.gov. However, notable progress has emerged in the research pipelines for the prevention and treatment of Atrial Fibrillation. Companies across the globe have taken the initiative working towards the development of suitable options for Atrial Fibrillation. Key players, such as Anthos Therapeutics (MAA868), HUYABIO International (HBI-3000), and others are involved in developing treatment for Atrial Fibrillation.

MAA868 (Anthos Therapeutics) is a novel, fully human, potent Factor XI antibody that uniquely binds with high affinity both active enzyme and zymogen. Single subcutaneous doses of MAA868 in a clinical study exhibited strong long-lasting anticoagulant activity in humans and a promising safety profile. MAA868 effectively reduces Factor XI for more than 4 weeks, representing a potential once-monthly subcutaneous anti-thrombotic agent. Currently it is in Phase II stage of development for the treatment of atrial fibrillation.

HBI-3000 (HUYABIO International) is a multi-ion channel blocker in development for the treatment of cardiac arrhythmias. Anti-arrhythmic drugs are used to treat patients with Atrial Fibrillation, a serious condition that affects more than 3.5 million patients in the US and 30 million patients worldwide. There is a significant need for safer and more effective pharmacological interventions to treat AF, as current treatments have poor safety and efficacy profiles and the alternative, electrical cardioversion, has poor patient acceptance and requires patient sedation.

HBI-3000 has a unique ion channel profile (INa-Peak, INa-Late, ICa,L and IKr, as well as some activity at Ito and IKur) and does not pose a pro-arrhythmic risk in preclinical models. The drug’s preclinical pharmacology also supports the potential of HBI-3000 to restore sinus rhythm in Atrial Fibrillation. This profile makes HBI-3000 a promising antiarrhythmic candidate for clinical development.

A Phase I randomized, double-blind, placebo-controlled, serial cohort dose escalation study of HBI-3000 has been completed in the UK and the results were published at the American Heart Association conference in November 2019. A second Phase I study to examine HBI-3000 metabolism and potential effects on contractility is underway in Australia, and a Phase II dose escalation study to evaluate the efficacy of HBI-3000 to convert patients in acute AF has been initiated in New Zealand.

Note: Detailed emerging therapies assessment will be provided in the full report of Atrial Fibrillation

Atrial Fibrillation Market Outlook

In the past few decades, research into AF has increased tremendously. With it, understanding of AF pathophysiology and treatment options has improved as well. Drugs targeting specific ion channels are approaching the early stages of clinical investigation. There are also new and exciting areas of AF research such as gene therapy, cell therapy, and microRNAs and their function on tissue remodeling. With the aging population and ever increasing prevalence of AF, optimized treatment plans for individuals with AF are essential. However, while advances in technologies have helped elucidate many aspects of AF, many mysteries remain. With continued research and into AF, the researchers can expect more effective drug therapies and ablation techniques to be developed soon.

The other factors that shall further expedite the growth of the Atrial Fibrillation market include its increasing morbidity rate and increasing awareness about available treatments during the forecast period (2019–2032). A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Atrial Fibrillation.

According to DelveInsight, Atrial Fibrillation market in 7MM is expected to witness a major change in the study period 2019-2032.

Analyst Commentary

• The pipeline of Atrial Fibrillation is very robust, many potential therapies are being investigated for the treatment of Atrial Fibrillation, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.
• The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate, are likely to boost the growth of the Atrial Fibrillation market in the 7MM. Aside from that, the market size of Atrial Fibrillation may flourish due to increased research and development, label-expansion of approved therapies into other epilepsy in this field.
• The market growth of Atrial Fibrillation may offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists.

Atrial Fibrillation Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Atrial Fibrillation market or expected to get launched in the market during the study period 2019-2032. The analysis covers Atrial Fibrillation market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Note: Detailed emerging therapies assessment will be provided in full report of Atrial Fibrillation.

Atrial Fibrillation Pipeline Development Activities

The Atrial Fibrillation report provides insights into Atrial Fibrillation Clinical Trials within Phase II and Phase III stage. It also analyses Atrial Fibrillation key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Atrial Fibrillation emerging therapies.

Reimbursement Scenario in Atrial Fibrillation

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs ' opinions working in the Atrial Fibrillation domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Atrial Fibrillation market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Atrial Fibrillation Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Atrial Fibrillation Market Report

• The report covers the descriptive overview of Atrial Fibrillation, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
• Comprehensive insight has been provided into the Atrial Fibrillation epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Atrial Fibrillation are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Atrial Fibrillation market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Atrial Fibrillation market

Atrial Fibrillation Market Report Highlights

• In the coming years, the Atrial Fibrillation market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Atrial Fibrillation R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Atrial Fibrillation. The launch of emerging therapies will significantly impact the Atrial Fibrillation market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Atrial Fibrillation
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Atrial Fibrillation Report Insights

• Atrial Fibrillation Patient Population
• Atrial Fibrillation Therapeutic Approaches
• Atrial Fibrillation Pipeline Analysis
• Atrial Fibrillation Market Size and Trends
• Atrial Fibrillation Market Opportunities
• Impact of Upcoming Atrial Fibrillation Therapies

Atrial Fibrillation Report Key Strengths

• 10 Years Forecast
• 7MM Coverage
• Atrial Fibrillation Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Atrial Fibrillation Drugs Uptake

Atrial Fibrillation Report Assessment

• Current Atrial Fibrillation Treatment Practices
• Atrial Fibrillation Unmet Needs
• Atrial Fibrillation Pipeline Product Profiles
• Atrial Fibrillation Market Attractiveness
• Atrial Fibrillation Market Drivers
• Atrial Fibrillation Market Barriers

Key Questions Naswered In The Atrial Fibrillation Market Report

Atrial Fibrillation Market Insights:

• What was the Atrial Fibrillation drug class share (%) distribution in 2019 and how it would look like in 2032?
• What would be the Atrial Fibrillation total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
• What are the key findings of the market across 7MM and which country will have the largest Atrial Fibrillation market size during the forecast period (2019-2032)?
• At what CAGR, the Atrial Fibrillation market is expected to grow by 7MM during the forecast period (2019-2032)?
• What would be the Atrial Fibrillation market outlook across the 7MM during the forecast period (2019-2032)?
• What would be the Atrial Fibrillation market growth till 2032, and what will be the resultant market Size in the year 2032?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Atrial Fibrillation Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Atrial Fibrillation?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 (Germany, France, Italy Spain) and the United Kingdom, and Japan?
• What is the historical Atrial Fibrillation patient pool in seven major markets covering the United States, EU4 (Germany, France, Italy Spain) and the United Kingdom, and Japan?
• What would be the forecasted patient pool of Atrial Fibrillation in seven major markets covering the United States, EU4 (Germany, France, Italy Spain) and the United Kingdom, and Japan?
• Where will be the growth opportunities in the 7MM concerning the patient population about Atrial Fibrillation?
• Out of all 7MM countries, which country would have the highest prevalent population of Atrial Fibrillation during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

Current Atrial Fibrillation Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the Atrial Fibrillation treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Atrial Fibrillation in the United States, EU4 (Germany, France, Italy Spain) and the United Kingdom, and Japan?
• What are the Atrial Fibrillation marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of Atrial Fibrillation?
• How many therapies are in-development by each company for Atrial Fibrillation treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Atrial Fibrillation treatment?
• What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Atrial Fibrillation therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Atrial Fibrillation and its status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Atrial Fibrillation?
• What are the global historical and forecasted markets of Atrial Fibrillation?

Reasons to buy Atrial Fibrillation Market Report

• The report will help in developing business strategies by understanding trends shaping and driving the Atrial Fibrillation market
• Organize sales and marketing efforts by identifying the best opportunities for Atrial Fibrillation in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for the Atrial Fibrillation market
• To understand the future market competition in the Atrial Fibrillation market
• DelveInsight's " Atrial Fibrillation— Market Insights, Epidemiology, and Market Forecast — 2032" report delivers an in-depth understanding of the Atrial Fibrillation, historical and forecasted epidemiology as well as the Atrial Fibrillation market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.
• The Atrial Fibrillation market report provides current treatment practices, emerging drugs, Atrial Fibrillation market share of the individual therapies, current and forecasted Atrial Fibrillation market size from 2019 to 2032 segmented by seven major markets. The report also covers current Atrial Fibrillation treatment practice/algorithm, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.